Odyssey Therapeutics, Inc. ODTX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +19.00%
- 1 year
- +19.00%
- Open
- 19.77
- Prev close
- 19.83
- Mkt cap
- 939.06M
- Vol
- 166.40K
- Avg vol
- 262.12K
- EPS
- -7.55
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.12
- High
- 20.20
- Forward P/E
- -4.78
- Beta
- 0.00
- Short ratio
- 11.58
- Inst. own
- 83.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 22.53
- 200-d avg
- 19.92
- 1y target
- 35.75
News
1 week ago marketbeat.com
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
Odyssey Therapeutics NASDAQ: ODTX presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its…
1 week ago seekingalpha.com
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
1 week ago globenewswire.com
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in IBD
-
2 weeks ago benzinga.com
UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27
UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.
2 weeks ago 247wallst.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More
Big banks kick off third-quarter earnings season tomorrow, and Wall Street analysts are already reshuffling their bets with a wave of surprise upgrades, downgrades, and fresh initiations across some…
-
2 weeks ago benzinga.com
Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and
-
3 weeks ago benzinga.com
Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42
Raymond James analyst Thomas Deal initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $42.
3 weeks ago globenewswire.com
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX)…
3 weeks ago defenseworld.net
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages
Shares of Odyssey Therapeutics, Inc. (NASDAQ: ODTX - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings…
1 month ago seekingalpha.com
Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care…
2 months ago benzinga.com
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.
-
2 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $44.
2 months ago globenewswire.com
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care…
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29
JP Morgan analyst Brian Cheng maintains Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight and raises the price target from $26 to $29.
2 months ago gurufocus.com
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases PR Newswire
-
2 months ago benzinga.com
Odyssey Taps Evotec's AI-Driven Discovery Platform To Advance Autoimmune, Inflammatory Disease Programs
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of…
2 months ago prnewswire.com
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of…
2 months ago globenewswire.com
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase…
-
4 months ago benzinga.com
Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target
Oppenheimer analyst Jeff Jones reiterates Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform and maintains $40 price target.
-
4 months ago benzinga.com
Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) Estimate
Odyssey Therapeutics (NASDAQ:ODTX) reported quarterly losses of $(6.77) per share which missed the analyst consensus estimate of $(1.13) by 499.12 percent. This is a 82.8 percent increase over losses…
4 months ago globenewswire.com
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on…
-
5 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Odyssey Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating.
-
5 months ago benzinga.com
Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30
Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $30.
-
5 months ago benzinga.com
JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26
JP Morgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating and announces Price Target of $26.
5 months ago benzinga.com
This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for all changes. MOBI target prices: $16, $19, $31
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
5 months ago benzinga.com
Doximity, Aeluma, PDF Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures rise on Dow gaining 200 points. Doximity (DOCS) shares drop 21.3% after reporting mixed Q4 results and weak guidance. Other stocks also decline in pre-market trading.
5 months ago gurufocus.com
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
Healthcare IPO demand is coming back, but investors are not giving every new listing an easy first-day win. Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI)
5 months ago globenewswire.com
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from…
9 months ago businesswire.com
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics announced the appointment of Jolie M. Siegel, Executive Vice President, General Counsel.
11 months ago businesswire.com
Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development
BOSTON--(BUSINESS WIRE)--Dennis Dean, Ph.D., appointed as Executive Vice President and Head of Non-Clinical Development at Odyssey Therapeutics.
1 year ago businesswire.com
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
BOSTON--(BUSINESS WIRE)--Odyssey announces appointment of Nia Tatsis, Ph.D., EVP of Vertex Pharmaceuticals, to its Board of Directors.
1 year ago globenewswire.com
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
1 year ago businesswire.com
Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics today announced the closing of a $213 million Series D financing.